248 related articles for article (PubMed ID: 22957772)
1. Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder.
Bukstein OG; Head J
Expert Opin Pharmacother; 2012 Oct; 13(15):2207-13. PubMed ID: 22957772
[TBL] [Abstract][Full Text] [Related]
2. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Childress AC
Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
[TBL] [Abstract][Full Text] [Related]
3. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
Faraone SV; McBurnett K; Sallee FR; Steeber J; López FA
Clin Ther; 2013 Nov; 35(11):1778-93. PubMed ID: 24139092
[TBL] [Abstract][Full Text] [Related]
4. Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD).
Sallee FR; Eaton K
Expert Opin Pharmacother; 2010 Oct; 11(15):2549-56. PubMed ID: 20831361
[TBL] [Abstract][Full Text] [Related]
5. Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
Rizzo R; Martino D
Expert Rev Neurother; 2015 Apr; 15(4):347-54. PubMed ID: 25800130
[TBL] [Abstract][Full Text] [Related]
6. Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents.
Connor DF; Arnsten AF; Pearson GS; Greco GF
Expert Opin Pharmacother; 2014 Aug; 15(11):1601-10. PubMed ID: 24992513
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
Newcorn JH; Stein MA; Childress AC; Youcha S; White C; Enright G; Rubin J
J Am Acad Child Adolesc Psychiatry; 2013 Sep; 52(9):921-30. PubMed ID: 23972694
[TBL] [Abstract][Full Text] [Related]
9. A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders.
Sallee F; Connor DF; Newcorn JH
J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):308-19. PubMed ID: 23782125
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
Sikirica V; Haim Erder M; Xie J; Macaulay D; Diener M; Hodgkins P; Wu EQ
Pharmacoeconomics; 2012 Aug; 30(8):e1-15. PubMed ID: 22788263
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents.
Childress A; Hoo-Cardiel A; Lang P
Expert Opin Pharmacother; 2020 Mar; 21(4):417-426. PubMed ID: 31971448
[No Abstract] [Full Text] [Related]
12. Guanfacine extended-release (intuniv) for ADHD.
Med Lett Drugs Ther; 2010 Oct; 52(1349):82-3. PubMed ID: 21045757
[No Abstract] [Full Text] [Related]
13. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
Erder MH; Xie J; Signorovitch JE; Chen KS; Hodgkins P; Lu M; Wu EQ; Sikirica V
Appl Health Econ Health Policy; 2012 Nov; 10(6):381-95. PubMed ID: 23113551
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder.
Sallee FR; Kollins SH; Wigal TL
J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):206-14. PubMed ID: 22612526
[TBL] [Abstract][Full Text] [Related]
16. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
Wilens TE; Bukstein O; Brams M; Cutler AJ; Childress A; Rugino T; Lyne A; Grannis K; Youcha S
J Am Acad Child Adolesc Psychiatry; 2012 Jan; 51(1):74-85.e2. PubMed ID: 22176941
[TBL] [Abstract][Full Text] [Related]
17. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
Kollins SH; López FA; Vince BD; Turnbow JM; Farrand K; Lyne A; Wigal SB; Roth T
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):111-20. PubMed ID: 21476931
[TBL] [Abstract][Full Text] [Related]
18. Impact of a Step Therapy for Guanfacine Extended-Release on Medication Utilization and Health Care Expenditures Among Individuals Receiving Treatment for ADHD.
Suehs BT; Sikirica V; Mudumby P; Dufour R; Patel NC
J Manag Care Spec Pharm; 2015 Sep; 21(9):793-802, 802a-802i. PubMed ID: 26308226
[TBL] [Abstract][Full Text] [Related]
19. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
Lachaine J; Sikirica V; Mathurin K
BMC Psychiatry; 2016 Jan; 16():11. PubMed ID: 26774811
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.
Chan E; Fogler JM; Hammerness PG
JAMA; 2016 May; 315(18):1997-2008. PubMed ID: 27163988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]